94 related articles for article (PubMed ID: 19517319)
1. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
Tiwari A
IDrugs; 2009 Jun; 12(6):381-93. PubMed ID: 19517319
[TBL] [Abstract][Full Text] [Related]
2. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
3. Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity.
Digesu GA; Verdi E; Cardozo L; Olivieri L; Khullar V; Colli E
Urology; 2012 Jul; 80(1):48-54. PubMed ID: 22626580
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
5. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
6. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
7. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
[TBL] [Abstract][Full Text] [Related]
9. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
[TBL] [Abstract][Full Text] [Related]
10. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
J Med Assoc Thai; 2007 Nov; 90(11):2301-9. PubMed ID: 18181311
[TBL] [Abstract][Full Text] [Related]
11. [The pathophysiology underlying overactive bladder syndrome possibly due to benign prostatic hyperplasia].
Akino H; Maegawa M; Nagase K; Tanaka I; Nakai M; Ishida Y; Oyama N; Miwa Y; Yokoyama O
Hinyokika Kiyo; 2008 Jun; 54(6):449-52. PubMed ID: 18634444
[TBL] [Abstract][Full Text] [Related]
12. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
J Med Assoc Thai; 2007 Sep; 90(9):1821-7. PubMed ID: 17957925
[TBL] [Abstract][Full Text] [Related]
13. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
Adorini L; Penna G; Fibbi B; Maggi M
Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
19. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
20. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
